Business Context and Reporting Period
This Form 8-K Current Report was filed by PMV Pharmaceuticals, Inc. on January 4, 2024, covering events occurring on January 4 and January 5, 2024. The filing primarily addresses significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the departure of the Chief Operating Officer, Chief Financial Officer, and Chief Medical Officer.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and transition arrangements.
- New CFO Base Salary: $370,000 annually.
- New CFO Target Cash Bonus: 40% of base salary.
- Outgoing COO/CFO Retainer: $20,000 per month for advisory services through March 31, 2024.
- Outgoing CMO Lump Sum Payment: $76,381.50.
- Outgoing CMO Transition Rate: $500 per hour for services through March 31, 2024.
- Outgoing CMO Equity: Continued vesting of 34,800 unvested restricted stock shares.
Material Changes
The filing reports the following material changes in corporate governance and personnel:
- Appointment of CFO: Michael Carulli was appointed Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective January 5, 2024. He previously served as Senior Vice President of Finance since March 2023.
- Departure of COO/CFO: Winston Kung transitioned from his roles as Chief Operating Officer and CFO, effective January 4, 2024. He will serve as an advisor through March 31, 2024.
- Departure of CMO: Leila Alland, M.D., transitioned from her role as Chief Medical Officer, effective January 5, 2024. She will serve as an advisor through March 31, 2024.
- Reason for Departures: The filing explicitly states that the departures of Mr. Kung and Dr. Alland are not related to any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks. It notes that Mr. Carulli's employment is at-will and that he is covered by the Company's Change in Control and Severance Policy. The document references a press release issued on January 5, 2024, which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the employment agreement for Michael Carulli, which is expected to be filed as an exhibit to a subsequent periodic report.
- Review the "Kung Transition Agreement" and "Alland Separation Letter" once filed as exhibits to understand the full scope of severance and advisory obligations.
- Confirm the status of the 34,800 restricted stock shares awarded to Dr. Alland and their impact on the company's equity plan.
- Monitor future filings for the appointment of a new Chief Medical Officer and Chief Operating Officer, as these roles are currently transitioning.